Tiziana Life Sciences Ltd.: StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.'s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced

Related Keywords

Milan ,Lombardia ,Italy ,London ,City Of ,United Kingdom ,Irina Koffler ,Hana Malik ,Milan University Medical School ,Lifesci Advisors ,Nasdaq ,Stem Cell Pathobiology Lab ,Accustem Sciences Inc ,Tiziana Life Sciences Ltd ,Accustem Sciences Ltd ,European Institute Of Oncology ,Business Development ,Life Sciences ,Accustem Sciences ,European Journal ,European Institute ,Royal Marsden Hospital ,Breast Cancer ,Salvatore Pece ,Full Professor ,Hormone Related Cancers ,Investor Relations ,Sci Advisors ,Tiziana ,Life ,Ciences ,Temprinter ,Emonstrates ,Prognostic ,Utility ,Ransatac ,Cohort ,